Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Honedra (CLBS12) in CLI due to ASO or Buerger's Disease
NCT02501018Phase 2Completed
- Sponsor
- Lisata Therapeutics
- Start
- Nov 2017
- Primary completion
- May 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of honubicistmut-L in critical limb ischemia (CLI), arteriosclerosis obliterans, thromboangiitis obliterans (TAO), sponsored by Lisata Therapeutics. Started Nov 2017; status: completed.
02
Drugs
honubicistmut-L
03
Conditions
critical limb ischemia (CLI)arteriosclerosis obliteransthromboangiitis obliterans (TAO)
Beyond the preview
Go deeper on NCT02501018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501018.